15/03-2019 14:00:00: (ADDV-A.ST, ADDV-B.ST, ADDVISE-001.ST) ADDvise Group receives order worth 2,7 MSEK - Regulatory information

ADDvise Group AB's (publ) subsidiary LabRum has received an order from a biotechnology company focusing on tomorrow's biopharmaceutical, to a value of 2,7 MSEK. The order relates to laboratory furniture for a newly built laboratory. Delivery is planned to Q2 2019.

For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se 

Important information: 

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on March 15, 2019 at 14:00 CET.

About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Rikard Akhtarzand, VD
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Ekstern link: https://news.cision.com/addvise/r/addvise-group-receives-order-worth-2-7-msek---regulatory-information,c2764250
Ekstern link: https://mb.cision.com/Main/12334/2764250/1007999.pdf

Nyheten er levert av Cision.